High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich -2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration.
Computing, Health and Science
Exercise, Biomedical and Health Science, Centre for Exercise and Sports Science Research
Insulin-like growth factor-I (IGF-I) is a known biomarker of recombinant human growth hormone (rhGH) abuse, and is also used clinically to confirm acromegaly. The protein leucine-rich α-2-glycoprotein (LRG) was recently identified as a putative biomarker of rhGH administration. The combination of an ACN depletion method and a 5-min ultra-high-performance liquid chromatography/tandem mass spectrometry (uHPLC/MS/MS)-based selected reaction monitoring (SRM) assay detected both IGF-I and LRG at endogenous concentrations. Four eight-point standard addition curves of IGF-I (16–2000 ng/mL) demonstrated good linearity (r2 = 0.9991 and coefficients of variance (CVs)